Aditxt files amended 8-K with Evofem unaudited interim financials for H1 2025

Aditxt, Inc.

Evofem H1 2025 revenue $5.67M, net loss $0.83M (unaudited).
Pro forma combined net loss of $15.99M for six months ended June 30, 2025.
Acquisition consideration: $116.5M total ($99.1M convertible preferred, $1.8M cash, $15.7M notes).
Preliminary goodwill $134.6M; intangible asset (SOLOSEC) $4.7M with 16-year life.
Merger consummation extended to Sept 30, 2025 per Fifth Amendment.

item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.